2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Clinical Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Devices, Surgical, Women’s Health, Biological Processes, Pathogenesis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, VWD, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4809 Comparative efficacy of marstacimab versus emicizumab, concizumab, and fitusiran in patients with hemophilia A or B with inhibitors: Results from unanchored matching-adjusted indirect comparisons

Maria Gheorghe, PhD, Monica Ines, PhD2, Joseph C Cappelleri3, Haitao Chu, MD, PhD4, Pengling Sun, PhD5, Hae Kyung Kim, MSc6, Devon J Boyne, PhD7, Tommy Lan, MSc8, Kristina Lindsley, PhD9
1 Pfizer, Inc., Bucharest, Romania
2 Pfizer, Inc., Lisbon, Portugal
3 Pfizer, Inc., New York, New York, United States
4 Pfizer, Inc., New York, New York, United States
5 Pfizer, Inc., Cambridge, Massachusetts, United States
6 Pfizer, Inc., New York, New York, United States
7 IQVIA, Inc., Kirkland, Quebec, Canada
8 IQVIA, Inc., Kirkland, Quebec, Canada
9 IQVIA, Inc., Falls Church, Virginia, United States

BACKGROUND: The development of inhibitors is a major treatment challenge in hemophilia A (HA) and hemophilia B (HB). Marstacimab, a monoclonal antibody targeting tissue factor pathway inhibitor, has demonstrated clinically meaningful reductions in bleeding rates in patients with HA or HB with inhibitors. In the absence of head-to-head studies, matching-adjusted indirect comparisons (MAICs) were conducted to evaluate the efficacy of marstacimab relative to other non-factor prophylactic therapies approved for patients with inhibitors.

METHODS: Unanchored MAICs were conducted using individual patient data from the BASIS trial (marstacimab) and published aggregate data from comparator trials identified from a systematic review conducted in December 2025, including HAVEN 1 (emicizumab), Explorer7 (concizumab), and ATLAS-OLE (fitusiran). Separate unanchored MAICs were performed for each comparison, adjusting for key baseline characteristics based on prognostic relevance and cross-trial imbalance. Hemophilia type and follow-up duration in BASIS was further restricted within the analyses to align with the comparator trials as appropriate. Outcomes of interest were treated annualized bleeding rate (ABR) and total ABR. Results were analyzed as rate ratios (RRs) with 95% confidence intervals (CIs), with RR <1 favoring marstacimab. Statistical tests were two-sided at a 5% significance level.

RESULTS: Patient characteristics: All participants were male aged ≥12 years, with HA or HB with inhibitors, and received on-demand bypassing agent therapy before trial entry. BASIS enrolled 48 patients (mean age 28.2 years; 52.1% Asian; 83.3% HA). HAVEN 1 included 35 patients (mean age 35.8 years; 28.6% Asian; 100% HA). Explorer7 included 33 patients (mean age 24.9 years; 45.2% Asian; 54.5% HA). ATLAS-OLE included 38 patients (median age 26 years; 71.0% Asian; 78.0% HA).

Marstacimab vs emicizumab (HA): After adjustment for baseline imbalances in age (mean) and race (% Asian), marstacimab was associated with a significantly lower treated ABR than emicizumab after approximately 52 weeks of follow-up (effective sample size (ESS)=27.6). Estimated treated ABR was 0.66 (95% CI 0.37-1.18) for marstacimab and 2.40 (95% CI 1.34-4.30) for emicizumab, corresponding to a 72% reduction in treated bleeds (RR [95% CI], 0.28 [0.12-0.63]; p=0.002). Total ABR was numerically lower with marstacimab (3.77 [95% CI 1.70-8.34] vs 4.47 [95% CI 2.83-7.06]), but was not statistically significant (RR [95% CI], 0.84 [0.34-2.11]; p=0.716).

Marstacimab vs concizumab (HA/HB): Marstacimab demonstrated numerically lower bleeding rates than concizumab after adjusting for baseline differences in age (mean) and target joints (% with ≥1 target joints) at approximately 40.1 weeks (ESS=29.3). Estimated treated ABR was 1.17 (95% CI 0.69-1.97) for marstacimab versus 1.70 (95% CI 1.01-2.87) for concizumab (RR [95% CI], 0.69 [0.33-1.43]; p=0.315) corresponding to a 31% reduction in treated bleeds. Total ABR was also lower with marstacimab (3.32 [95% CI 1.96-5.62] vs 4.41 [95% CI 2.84-6.86]; RR [95% CI], 0.75 [0.38-1.49]; p=0.416). RRs did not reach statistical significance.

Marstacimab vs fitusiran (HA/HB): Marstacimab was associated with significantly lower treated ABR than fitusiran after adjusting for baseline imbalances in race (% Asian) and the number of bleeding events in the prior 24 weeks (mean) at approximately 28 weeks (ESS=38.1). Estimated treated ABR was 1.75 (95% CI 1.04-2.97) for marstacimab versus 5.14 (95% CI 2.78-9.51) for fitusiran, representing a 66% reduction in treated bleeding events (RR [95% CI], 0.34 [0.15-0.77]; p=0.009). Total ABR was not reported in the ATLAS-OLE study and could not be compared.

CONCLUSIONS: Across population-adjusted indirect comparisons, marstacimab demonstrated significantly lower treated ABR than emicizumab and fitusiran in patients with HA or HB with inhibitors. Total ABR comparisons versus emicizumab numerically favored marstacimab but were not statistically significant. Comparisons with concizumab also numerically favored marstacimab for treated and total ABR, although RRs were not statistically significant. These findings suggest that marstacimab may provide comparable or improved bleed protection relative to available non-factor prophylactic therapies. As with all unanchored indirect comparisons, results should be interpreted considering small sample size, potential residual confounding, and differences between trial populations.

Hae Kyung Kim, MSc: Pfizer, Inc. - Current equity holder in publicly-traded company; Pfizer, Inc. - Current Employment